Year 2007
	» January 2007 » February 2007 » March 2007 » April 2007 » May 2007 » June 2007 » July 2007 »September 2007
	Archives » Archive 2006 » Archive 2005 » Archive 2004
	News Home

September 2005»

A New Erectile Dysfunction Drug to Arrive in the Market Soon

VIVUS, Inc., the U.S. based pharmaceutical company is a pioneer in the research and development of proprietary products to restore sexual function for women and men. VIVUS' current product pipeline includes four investigational products in late stage clinical development.

For men, VIVUS is developing avanafil for erectile dysfunction, a new competitor for the original ED drug Viagra. VIVUS currently markets MUSE® (alprostadil) suppository for the treatment of erectile dysfunction in the U.S. and internationally through distributors.

For women, VIVUS has initiated a Phase 2B program with ALISTA(TM) for female sexual arousal disorder and a Phase 3 program for Evamist(TM) for the alleviation of menopausal symptoms. Testosterone MDTS® for the treatment of hypoactive sexual desire disorder has completed Phase 2 development. The MDTS system is a patented new-generation, transdermal drug delivery technology that delivers drugs through the skin.

Read the complete news article here:
: http://biz.yahoo.com/prnews/050920/sftu141.html?.v=12